Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-009280
Filing Date
2025-05-08
Accepted
2025-05-08 16:30:31
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 812892
2 EX-31.1 ex31-1.htm EX-31.1 14236
3 EX-31.2 ex31-2.htm EX-31.2 14887
4 GRAPHIC form10-q_001.jpg GRAPHIC 22502
  Complete submission text file 0001641172-25-009280.txt   5237763

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE immx-20250331.xsd EX-101.SCH 42524
6 XBRL CALCULATION FILE immx-20250331_cal.xml EX-101.CAL 54176
7 XBRL DEFINITION FILE immx-20250331_def.xml EX-101.DEF 184443
8 XBRL LABEL FILE immx-20250331_lab.xml EX-101.LAB 414427
9 XBRL PRESENTATION FILE immx-20250331_pre.xml EX-101.PRE 325251
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 673006
Mailing Address 10573 W. PICO BLVD. #58 LOS ANGELES CA 90064
Business Address 11400 WEST OLYMPIC BLVD. SUITE 200 LOS ANGELES CA 90064 (888) 958-1084
Immix Biopharma, Inc. (Filer) CIK: 0001873835 (see all company filings)

EIN.: 454869378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41159 | Film No.: 25926788
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)